

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FIĽING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/646,899	10/10/2000	Tomoko Maeda	197679US0PCT	6173
22850	7590 05/23/2002		, e	
OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC			EXAMINER	
FOURTH FLOOR \\ 1755 JEFFERSON DAVIS HIGHWAY			AFREMOVA, VERA	
ARLINGTON	, VA 22202		ART UNIT	PAPER NUMBER
	<u>,</u>		1651	B
	,		DATE MAILED: 05/23/2002	1

Please find below and/or attached an Office communication concerning this application or proceeding.



## Office Action Summary

Application No.

Applicant(s)

09/646,899

Maeda et al.

Examiner

Vera Afremova

Art Unit **1651** 

The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period fo	or Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.					
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the					
- If the pe - If NO pe - Failure t	o reply within the set or extended period for reply will, by statute, cause th	nd will expire SIX (6) MONTHS from the mailing date of this communication. e application to become ABANDONED (35 U.S.C. § 133).			
	ly received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	nis communication, even if timely filed, may reduce any			
Status					
1) 💢	Responsive to communication(s) filed on Oct 10, 20	000			
2a) 🗌	This action is <b>FINAL</b> . 2b) 💢 This acti	ion is non-final.			
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.				
	ion of Claims				
4) 💢	Claim(s) <u>1-17</u>	is/are pending in the application.			
4	a) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	is/are allowed.			
6) 🗆	Claim(s)	is/are rejected.			
7) 🗆	Claim(s)	is/are objected to.			
8) 💢	Claims <u>1-17</u>	are subject to restriction and/or election requirement.			
Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)	The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.			
	If approved, corrected drawings are required in reply t	to this Office action.			
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) □ Some* c) □ None of:					
1. ☐ Certified copies of the priority documents have been received.					
2	2. $\square$ Certified copies of the priority documents hav	e been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
*See the attached detailed Office action for a list of the certified copies not received.					
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
a) In the translation of the foreign language provisional application has been received.  15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)					
		4) Interview Summary (PTO-413) Paper No(s).			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).		5) Notice of Informal Patent Application (PTO-152)  6) Other:			
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Information Disclosure Statement(s) (PTO-1449) Paper No(s) (					

Art Unit: 1651

## **DETAILED ACTION**

Claims 1-17 are pending and subject to restriction requirement.

## Restriction

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-4 and 8-11, drawn to a method for differentiating osteoclast precursor cells.

Group II, claim(s) 5 and 6, drawn to a method for isolating osteoclast precures or cells.

Group III, claim(s) 7, drawn to an osteoclast precursor cell.

Group IV, claim(s) 12, drawn to an osteoclast cell. + d. |8 (milim non) Am Group V, claim(s) 13 and 14, drawn to a method for screening agents by using osteoclast precurosor cells.

Group VI, claim(s) 15 and 16, drawn to a method for screening agents by using

osteoclast cells.

Group VII, claim(s) 17, drawn to an agent for metabolic bone diseases.

H. (203) 412-6461 Oblion. discurred 5/30/02 V.A. Art Unit: 1651

The inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 and under PCT Rule 13.2 because this application contain claims to more than one of permissible combinations of categories of invention and because the same or corresponding special technical features within a permissible combination of categories of invention is already known in the art, thus, the claims are lacking the same or corresponding special technical features which makes a contribution over the prior art.

37 CFR1.475. Unity of invention before the International Searching Authority, the International Preliminary Examining Authority and during the national stage.

- (a) An international and a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention"). Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.
- (b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:
- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and a process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.
- © If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present.
- (d) If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each of the other categories related thereto will be considered as the main invention in the claims, see PCT Article 17(3)(a) and § 1.476(c).
- (e) The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

For example: the claimed inventions of groups III, IV and VII are directed to three distinct products such as an osteoclast precursor cell, an osteoclast cells and an agent for metabolic bone diseases. Each product as claimed is obtained by a distinct method of making by using various culture media as claimed and by using screening protocols as claimed. Each claimed product is intended for a different method of use as claimed. Further, cellular products

Application/Control Number: 09/646,899

Page 4

Art Unit: 1651

such as osteoclast precursor cell and differentiated osteoclast cells are known the prior art, for example: see WO 96/07733 at page 29, lines 32-34. Therefore, the inventions listed above are distinct and they do not relate to a single general inventive concept as explained above.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vera Afremova whose telephone number is (703) 308-9351. The examiner can normally be reached on Monday to Friday from 9:00 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Vera Afremova,

Art Unit 1651

May 22, 2002.

There mark